Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren

Journal of Clinical Pharmacology

Volumn 50, Issue 12, 2010, Pages 1358-1366

  Jarugula, Venkateswar ^a   Yeh, Ching Ming ^a   Howard, Dan ^a   Bush, Christopher ^a   Keefe, Deborah L ^a   Dole, William P ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Blood pressure; body weight; direct renin inhibitor; pharmacokinetics; renin angiotensin system

Indexed keywords

ALISKIREN; AMLODIPINE; PLACEBO; RENIN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; FEMALE; HUMAN; HYPERTENSION; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE DRUG DOSE; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE BLIND PROCEDURE; WEIGHT REDUCTION;

ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS INDEX; BODY WEIGHT; CLINICAL TRIALS AS TOPIC; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; RENIN; SEX CHARACTERISTICS;

EID: 77956189544     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009359525     Document Type: Article

References (34)

1. Frampton JE, Curran MP Aliskiren: A review of its use in the management of hypertension. Drugs. 2007 ; 67: 1767-1792.
2. Limoges D., Dieterich H-A., Yeh C. -M, et al. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther. 2008 ; 46: 252-258. (Pubitemid 351663162)
3. Azizi M., Webb R., Nussberger J., Hollenberg NK Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006 ; 24: 243-256.
4. Waldmeier F., Glaenzel U., Wirz B., et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos. 2007 ; 35: 1418-1428.
5. Vaidyanathan S., Reynolds C., Yeh CM, et al. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol. 2007 ; 47: 453-460.
6. Vaidyanathan S., Bigler H., Yeh C., et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet. 2007 ; 46: 661-675.
7. Vaidyanathan S., Warren V., Yeh C., et al. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol. 2007 ; 47: 192-200. (Pubitemid 46146485)
8. Zhao C., Vaidyanathan S., Yeh C-M., et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with diabetes. Clin Pharmacokinet. 2006 ; 45: 1125-1134.
9. Vaidyanathan S., Jermany J., Yeh C., et al. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol. 2006 ; 62: 690-698.
10. Bartlett M., Vaidyanathan S., Karan RS, et al. Multiple-dose pharmacokinetics of the direct renin inhibitor aliskiren in healthy Chinese subjects. Clin Pharm Ther. 2008 ; 83 (suppl 1): S61. Abstract PII-62.
11. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000 ; 39: 215-231.
12. Romero R., Bonet J., de la Sierra A., et al. Undiagnosed obesity in hypertension: clinical and therapeutic implications. Blood Press. 2007 ; 16: 347-353.
13. Ayalasomayajula S., Tchaloyan S., Yeh C-M., et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Curr Med Res Opin. 2008 ; 24: 717-726.
14. Ayalasomayajula S., Yeh C. -M, Vaidyanathan S., et al. Effects of aliskiren, a direct renin inhibitor, on cardiac repolarization and conduction in healthy subjects. J Clin Pharmacol. 2008 ; 48: 799-811. (Pubitemid 351871965)
15. Vaidyanathan S., Valencia J., Kemp C., et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract. 2006 ; 60: 1343-1356.
16. Vaidyanathan S., Bartlett M., Dieterich H-A., et al. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. Cardiovasc Ther. 2008 ; 26: 238-246.
17. Vaidyanathan S., Maboudian M., Warren V., et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate, in healthy subjects. Curr Med Res Opin. 2008 ; 24: 2313-2326.
18. Vaidyanathan S., Camenisch G., Schuetz H., et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008 ; 48: 1323-1338.
19. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005 ; 111: 1012-1018.
20. Kushiro T., Itakura H., Abo Y., et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res. 2006 ; 29: 997-1005.
21. Oh BH, Mitchell J., Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007 ; 49: 1157-1163.
22. Pool JL, Schmieder RE, Azizi M., et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007 ; 20: 11-20.
23. Villamil A., Chrysant SG, Calhoun D., et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 ; 25: 217-226.
24. Nussberger J., Fasanella d-Amore T., Porchet M., et al. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol. 1987 ; 9: 39-44. (Pubitemid 17212750)
25. Janmahasatian S., Duffull SB, Ash S., et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005 ; 44: 1051-1065.
26. Han PY, Duffull SB, Kirkpatrick CM, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007 ; 82: 505-508.
27. Prescott MF, Boye SW, Le Breton S., et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren when added to hydrochlorothiazide treatment in patients with extreme obesity and hypertension. J Am Coll Cardiol. 2007 ; 49 (9supplA). 370A. Abstract P-1014-169.
28. Jordan J., Engeli S., Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension. 2007 ; 49: 1047-1055.
29. Blumenstein M., Romaszko J., Calderon A., et al. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) fixed-dose combination tablets in patients who are non-responsive to HCT 25 mg alone. Curr Med Res Opin. 2009 ; 25: 903-910.
30. Schmieder R., Philipp T., Guerediaga J., et al. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: subanalysis of a 52-week, randomized, double-blind trial. J Hypertens. 2009 ; 27: 1493-1501.
31. Krone W., Hanefeld M., Eckhardt G., et al. Comparative effects of aliskiren and irbesartan on blood pressure, renin system activity, and biomarkers of cardiometabolic risk in patients with hypertension and metabolic syndrome. Circulation. 2008 ; 118 (suppl 18): S889.
32. Frandsen E., Boomsma F., Persson F., et al. Aliskiren reduces renin system activity in patients with type 2 diabetes and albuminuria. Poster presented at: ASH ; May 14-17, 2008 ; N ew Orleans, La.
33. Vaidyanathan S., Jarugula V., Dieterich H-A., et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008 ; 47: 515-531.
34. Prescott MF, Bush C., Arora V., et al. Aliskiren, a direct renin inhibitor, provides effective blood pressure (BP) lowering with placebo-like tolerability in obese patients with hypertension. Int J Obes. 2007 ; 31: S99.